20160302 March April 2016 IR events ENG
Category: dates
Transgene and ABL Announce the Acquisition by ABL Europe of Transgene’s Production Asset
20160203 PR ABL TG SYMPHONY
EIB lends EUR 20m to Transgene
20160128 PR transgene BEI final version
Transgene Announces Financial Calendar for 2016
20160108 financial calendar_EN ver 1
Transgene enters new phase in its strategic development
20160107 Strategic update ENG clean
Transgene Announces First Patient Randomized in Multinational Phase 3 Trial for Pexa-Vec Oncolytic Immunotherapy in Advanced Liver Cancer
20160106 Ph 3 pexa vec in HCC trial initiation VER8
Transgene Announces Publication in “The Lancet Oncology” of Phase 2b TIME Trial Results with TG4010 Immunotherapy in Non-Small Cell Lung Cancer
20151223_TIME Ph2b Lancet Oncology 2015_PR EN
TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial
Elisabeth Quoix, et al. The Lancet Oncology, December 2015, 17: 212–23 – Download the article Publication
A Novel MVA-Based Multiphasic Vaccine for Prevention or Treatment of Tuberculosis Induces Broad and Multifunctional Cell-Mediated Immunity in Mice and Primates
Stephane Leung-Theung-Long, et al. PLOS One, November 24, 2015 DOI: 10.1371/journal.pone.0143552 – Download the article Publication
TG4010 immunotherapy plus chemotherapy as first-line treatment of advanced NSCLC: Phase 2b Results of the TIME trial
John Nemunaitis, et al. SITC 2015, November 2015 – Abstract available on the SITC website Download the poster here Poster Presentation